1Sehnabel FIB, Sullivan LM, Levy D, et al. Development of a riskscore for atrial fibrillation (Framingham Heart Study ): a community-based cohort study. Lancet, 2009, 373: 739-745.
2Active Writing Group of the ACTIVE Investigators, Connolly S, Pogue J, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE W): A randomized controlled trial. Lancet, 2006, 367 : 1903-1912.
3ACTIVE Investigators, Connolly S J, Pogue J, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med, 2009, 360: 2066-2078.
4Turpie AG. "New oral anticoagulants in atrial fibrillation. Eur Heart J, 2008, 29: 155-165.
5Zikria JC, Ansell J. Oral anticoagulation with factor Xa and thrombin inhibitors: on the threshold of change. Curr Opin Hematol, 2009, 16: 347-356.
6Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: A double- blind, randomised controlled trial. Lancet, 2008, 372: 31-39.
7Executive Steering Committee on behalf of the ROCKET AF Study Investigators. Rivaroxaban-Once daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation : Rationale and Design of the ROCKET AF Study. Am Heart J, 2010, 159 : 340- 347.
8Cleland JG,Coletta AP, Buga L, et al. Clinical trials update from the American Heart Association Meeting 2010: EMPHASIS- HF, RAFT, TIM-HF, Tele-HF, ASCEND-HF, ROCKET-AF, and PROTECT. Eur J Heart Fail, 2011, 13 : 460-465.
9Samama MM, Gerotziafas GT. Newer anticoagulauts in 2009. J Thromb Thrombolysis, 2010, 29: 92-104.
10Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Phammcokinet, 2008, 47: 285-295.
3Hobbs FD,Fitzmaurice DA,Mant J,et al.A randomized controlled trial and cost-effectiveness study of systematic screening(targeted and total population screening)versus routine practice for the detection of atrial fibrillation in people aged65and over.The SAFE study[J].Health Technol Assess,2005,9(40):1-90.
4Holbrook A,Schulman S,Witt DM,et al.Evidence-based management of anticoagulant therapy:Antithrombotic Therapy and Prevention of Thrombosis,9th ed:American College of Chest Physicians Evidence-Based Clinical Practice Guidelines[J].Chest,2012,141(2Suppl):e152S-84S.
5Zhang K,Young C,Berger J.Administrative claims analysis of the relationship between warfarin use and risk of hemorrhage including drug-drug and drug-disease interactions[J].J Manag Care Pharm,2006,12(8):640-648.
6Horn JR,Hansten PD,Chan LN.Proposal for a new tool to evaluate drug interaction cases[J].Ann Pharmacother,2007,41(4):674-680.
7Baillargeon J,Holmes HM,Lin YL,et al.Concurrent use of warfarin and antibiotics and the risk of bleeding in older adults[J].Am J Med,2012,125(2):183-189.
8Ansell J,Hirsh J,Hylek E,et al.Pharmacology and Management of the Vitamin K Antagonists*:American College of Chest Physicians Evidence-Based Clinical Practice Guidelines(8th Edition)[J].Chest,2008,133(6Suppl):160S-198S.
9Clark TR,Burns S.Elevated international normalized ratio values associated with concomitant use of warfarin and ceftriaxone[J].Am J Health Syst Pharm,2011,68(17):1603-1605.
10Bohm NM,Crosby B.Hemarthrosis in a patient on warfarin receiving ceftaroline:a case report and brief review of cephalosporin interactionswithwarfarin[J].AnnPharmacother,2012,46(7-8):e19.
